Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2013

01-11-2013 | Breast Oncology

International Rates of Breast Reconstruction After Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers

Authors: John Semple, MD, Kelly A. Metcalfe, RN, PhD, Henry T. Lynch, MD, Charmaine Kim-Sing, MD, Leigha Senter, MS, CGC, Tuya Pal, MD, Peter Ainsworth, MD, Jan Lubinski, MD, PhD, Nadine Tung, MD, Charis Eng, MD, PhD, Donna Gilchrist, MD, Joanne Blum, MD, PhD, Susan L. Neuhausen, PhD, Christian F. Singer, MD, Parviz Ghadirian, PhD, Ping Sun, PhD, Steven A. Narod, MD, The Hereditary Breast Cancer Clinical Study Group

Published in: Annals of Surgical Oncology | Issue 12/2013

Login to get access

Abstract

Background

Breast reconstruction is an option for women with BRCA1 or BRCA2 mutations who elect to undergo prophylactic mastectomy to prevent breast cancer. We report on the uptake of breast reconstruction after prophylactic mastectomy in women with BRCA mutations from eight countries.

Methods

Women with a BRCA1 or BRCA2 mutation were questioned regarding their cancer preventive practices. Information was recorded on prophylactic mastectomy and breast reconstruction.

Results

A total of 1,635 women with a BRCA1 or BRCA2 mutation who elected to undergo prophylactic mastectomy from eight countries were included. A total of 1,137 women (69.5 %) had breast reconstruction after prophylactic mastectomy. A total of 58.7 % of women over the age of 45 years at the time of prophylactic mastectomy had breast reconstruction compared to 77.6 % of women 35 years of age or younger [odds ratio (OR) 0.36, 95 % confidence interval (CI) 0.26–0.50, p < 0.001]. In addition, 62.9 % of women with a breast cancer diagnosis (contralateral prophylactic mastectomy) had breast reconstruction after prophylactic mastectomy compared to 79.7 % of women without a previous breast cancer diagnosis (OR 0.48, 95 % CI 0.38–0.61, p < 0.001). A total of 66.9 % of women from Canada had breast reconstruction after mastectomy compared to 71.9 % of American women (OR 0.75, 95 % CI 0.59–0.96, p = 0.02).

Conclusions

The majority of women elect for breast reconstruction after prophylactic mastectomy. However, younger women and those without a previous diagnosis of breast cancer are more likely to have breast reconstruction than older women or those with a previous diagnosis of cancer.
Appendix
Available only for authorised users
Literature
1.
Antoniou AC, Shenton A, Maher ER, et al. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2006;8:R72.PubMedCrossRef
2.
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329–33.PubMedCrossRef
3.
Metcalfe K, Gershman S, Lynch HT, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104:1384–92.PubMedCrossRef
4.
Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328–35.PubMedCrossRef
5.
Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633–7.PubMedCrossRef
6.
Alderman AK, Hawley ST, Janz NK, et al. Racial and ethnic disparities in the use of postmastectomy breast reconstruction: results from a population-based study. J Clin Oncol. 2009;27:5325–30.PubMedCrossRef
7.
Hall SE, Holman CDcInequalities in breast cancer reconstructive surgery according to social and locational status in Western Australia. Eur J Surg Oncol. 2003;29:519–25.PubMedCrossRef
8.
Hvilsom GB, Holmich LR, Frederiksen K, et al. Socioeconomic position and breast reconstruction in Danish women. Acta Oncol. 2011;50:265–73.PubMedCrossRef
9.
Jeevan R, Cromwell DA, Browne JP, et al. Regional variation in use of immediate breast reconstruction after mastectomy for breast cancer in England. Eur J Surg Oncol. 2010;36:750–5.PubMedCrossRef
10.
Yu KD, Di GH, Wu J, et al. Development and trends of surgical modalities for breast cancer in China: a review of 16-year data. Ann Surg Oncol. 2007;14:2502–9.PubMedCrossRef
11.
Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008;122:2017–22.PubMedCrossRef
12.
Metcalfe KA, Snyder C, Seidel J, et al. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer. 2005;4:97–103.PubMedCrossRef
13.
Baxter N, Goel V, Semple JL. Rates and regional variation of breast reconstruction following mastectomy for breast cancer: viewpoint from a single payer medical system. 2002.
14.
Polednak AP. Postmastectomy breast reconstruction in Connecticut: trends and predictors. Plast Reconstr Surg. 1999;104:669–73.PubMed
15.
Alderman AK, McMahon L Jr, Wilkins EG. The national utilization of immediate and early delayed breast reconstruction and the effect of sociodemographic factors. Plast Reconstr Surg. 2003;111:695–703.PubMedCrossRef
16.
Polednak AP. How frequent is postmastectomy breast reconstructive surgery? A study linking two statewide databases. Plast Reconstr Surg. 2001;108:73–7.PubMedCrossRef
17.
Alderman AK, Wei Y, Birkmeyer JD. Use of breast reconstruction after mastectomy following the Women’s Health and Cancer Rights Act. JAMA. 2006;295:387–8.PubMed
18.
Joslyn SA. Patterns of care for immediate and early delayed breast reconstruction following mastectomy. Plast Reconstr Surg. 2005;115:1289–96.PubMedCrossRef
19.
Rosson GD, Singh NK, Ahuja N, et al. Multilevel analysis of the impact of community vs patient factors on access to immediate breast reconstruction following mastectomy in Maryland. Arch Surg. 2008;143:1076–81.PubMedCrossRef
20.
Tseng WH, Stevenson TR, Canter RJ, et al. Sacramento area breast cancer epidemiology study: use of postmastectomy breast reconstruction along the rural-to-urban continuum. Plast Reconstr Surg. 2010;126:1815–24.PubMedCrossRef
21.
Kruper L, Holt A, Xu XX, et al. Disparities in reconstruction rates after mastectomy: patterns of care and factors associated with the use of breast reconstruction in Southern California. Ann Surg Oncol. 2011;18:2158–65.PubMedCrossRef
22.
Morrow M, Scott SK, Menck HR, et al. Factors influencing the use of breast reconstruction postmastectomy: a National Cancer Data Base study. J Am Coll Surg. 2001;192:1–8.PubMedCrossRef
23.
Tseng JF, Kronowitz SJ, Sun CC, et al. The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer. 2004;101:1514–23.PubMedCrossRef
24.
Metcalfe KA, Goel V, Lickley L, et al. Prophylactic bilateral mastectomy: patterns of practice. Cancer. 2002;95:236–42.PubMedCrossRef
25.
Metcalfe KA, Lubinski J, Ghadirian P, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26:1093–7.PubMedCrossRef
Metadata
Title
International Rates of Breast Reconstruction After Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers
Authors
John Semple, MD
Kelly A. Metcalfe, RN, PhD
Henry T. Lynch, MD
Charmaine Kim-Sing, MD
Leigha Senter, MS, CGC
Tuya Pal, MD
Peter Ainsworth, MD
Jan Lubinski, MD, PhD
Nadine Tung, MD
Charis Eng, MD, PhD
Donna Gilchrist, MD
Joanne Blum, MD, PhD
Susan L. Neuhausen, PhD
Christian F. Singer, MD
Parviz Ghadirian, PhD
Ping Sun, PhD
Steven A. Narod, MD
The Hereditary Breast Cancer Clinical Study Group
Publication date
01-11-2013
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 12/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3040-4

Other articles of this Issue 12/2013

Annals of Surgical Oncology 12/2013 Go to the issue

Breast Oncology

Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Pancreatic Tumors

Phase II Study of Induction Fixed-Dose Rate Gemcitabine and Bevacizumab Followed by 30 Gy Radiotherapy as Preoperative Treatment for Potentially Resectable Pancreatic Adenocarcinoma

Gastrointestinal Oncology

The Impact of Neoadjuvant Chemoradiotherapy on Perioperative Outcomes, Tumor Pathology, and Survival in Clinical Stage II and III Esophageal Cancer

Endocrine Tumors

Discriminating Pheochromocytomas from Other Adrenal Lesions: The Dilemma of Elevated Catecholamines

Thoracic Oncology

Different Recurrence Pattern After Neoadjuvant Chemoradiotherapy Compared to Surgery Alone in Esophageal Cancer Patients

Hepatobiliary Tumors

Prediction of Disease-free Survival in Hepatocellular Carcinoma by Gene Expression Profiling